Phase I Dose Escalating Study to Evaluate the Safety, Tolerability, Anti-Tumour Activity and Pharmacokinetic and Pharmacodynamic Profiles of Foxy-5 in Patients With Metastatic Breast, Colon or Prostate Cancer
Phase of Trial: Phase I
Latest Information Update: 16 Feb 2016
Price : $35 *
At a glance
- Drugs Foxy 5 (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Prostate cancer
- Focus Adverse reactions
- Sponsors WntResearch
- 31 Aug 2018 Biomarkers information updated
- 13 Jan 2016 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 18 Jun 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Mar 2015 to 1 Aug 2015.